HAV

Humacyte Presents at Multiple Conferences in September 2022

Retrieved on: 
Thursday, September 8, 2022
International Committee for the Nanking Safety Zone, FACS, World Congress, Shock, Fast track (FDA), Tissue, Military medicine, USAF, ICMM, HAV, GLOBE, Medicine, Conference, Moyamoya disease, Nasdaq, Company, HUMA, HC, Lotte New York Palace Hotel, Vibration, Injury, Congress, Col, Patient, Pharmaceutical industry, Defense

USAF MC) at the 44th International Committee on Military Medicine (ICMM) World Congress was given on September 7, 2022.

Key Points: 
  • USAF MC) at the 44th International Committee on Military Medicine (ICMM) World Congress was given on September 7, 2022.
  • In addition, company management will represent Humacyte at the HC Wainwright 24th Annual Global Investment Conference on September 14, 2022.
  • The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.

Humacyte Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Friday, August 12, 2022
JAMA Surgery, HAV, University Hospital Heidelberg, Risk, Amputation, GLOBE, Investment, CABG, Conference call, Hospital, Trauma, Femoral artery, Tissue, Board, Research, Pharmacy, Income, Patient, Cell, HUMA, Company, Acquisition, BCVS, Circulation Research, Vibration, University of Southern California, Chronic kidney disease, Lists of people executed in the United States, Disease, Infection, Publication, Maintenance, KOL, Board of directors, Denver Health Medical Center, CPRA, Insurance, University, Nasdaq, University of Bonn, AstraZeneca, Time, Conference, Duke University, Dentistry, Management, Pharmaceutical industry, Medical device, Lithium

-- Conference call and live webcast at 8:00 a.m. ET today –

Key Points: 
  • ET today
    DURHAM, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and organs at commercial scale, today announced financial results for the second quarter ended June 30, 2022, and highlighted recent corporate accomplishments.
  • Early in the second quarter, Humacyte launched an initiative to provide its HAVs to hospitals in Ukraine for the treatment of wounded civilians and soldiers with vascular trauma injuries.
  • Revenue was $1.3 million for the second quarter of 2022, compared to $0.7 million for the second quarter of 2021, and was $1.5 million for the six months ended June 30, 2022, compared to $0.8 million for the six months ended June 30, 2021.
  • Other net income was $55.4 million for the second quarter of 2022, compared to $2.1 million for the second quarter of 2021, and was $57.3 million for the six months ended June 30, 2022, compared to $1.5 million for the six months ended June 30, 2021.

Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022

Retrieved on: 
Friday, August 5, 2022
HAV, Injury, Tissue, Patient, HUMA, Company, Moyamoya disease, Vibration, Fast track (FDA), Webcast, Nasdaq, Medicine, Broadcasting, Pharmaceutical industry, Defense

A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Companys website for at least 30 days.

Key Points: 
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Companys website for at least 30 days.
  • The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.
  • The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting

Retrieved on: 
Tuesday, July 26, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sale, Infection, GLOBE, American Heart, Injury, Saphenous, Fast track (FDA), Research, Food, Tissue, BCVS, Diabetes, Forward-looking statement, SEC, AV, Vibration, Partnership, Ligation, Histology, HAV, Intention, Risk, Safety, COVID-19, Duke University, Angiography, Technology, FDA, Company, HUMA, Patient, Heart, Nasdaq, Pain, Fresenius Medical Care, Annual report, Terminology, Risk-based testing, CABG, Animal, Moyamoya disease, Circulation Research, Medicine, Pharmaceutical industry, Medical imaging, Defense

DURHAM, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced results evaluating the use of the small-diameter (3.5mm) Human Acellular Vessel (HAV) for coronary artery bypass grafting (CABG) in a non-human primate model. The HAV was observed to maintain structural integrity and patency for up to six months post-implantation and showed evidence of robust host cell repopulation and remodeling. The results were presented by Adam Williams, M.D., cardiothoracic surgeon, Duke University, at the American Heart Association Basic Cardiovascular Sciences Scientific Sessions (BCVS) 2022 in Chicago, IL on July 25, 2022, and will be published in the September issue of Circulation Research.

Key Points: 
  • CABG is one of the most common surgical procedures, and we are often limited by our ability to find suitable conduit.
  • In the preclinical study, CABG surgery was performed using small-diameter HAVs implanted into seven non-immunosuppressed, non-human primates following ligation of the proximal coronary artery.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.

Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions

Retrieved on: 
Tuesday, July 19, 2022
Patient, Injury, Vibration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, BCVS, AV, GLOBE, Food, Fast track (FDA), Medicine, Company, HUMA, American Heart, FDA, Tissue, Moyamoya disease, HAV, Pharmaceutical industry, Defense

Details of the poster presentation are as follows:

Key Points: 
  • Details of the poster presentation are as follows:
    Sponsored by the American Heart Associations Basic Cardiovascular Sciences Council, the annual BCVS Scientific Sessions is one of largest meetings in the world dedicated to fundamental and translational research to improve heart health.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
  • Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.

Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

Retrieved on: 
Wednesday, June 29, 2022
FDA, Patient, Bypass, Journal, Blood vessel, Amputation, Uniformed Services University of the Health Sciences, Tissue, Dialysis, Vibration, GLOBE, AV, Infection, Walter Reed National Military Medical Center, Sale, Fast track (FDA), Company, Vascular disease, JAMA Surgery, Professor, Col, Moyamoya disease, Compliance, Publication, Food, Trauma, Regenerative medicine, USAF, Mayo Clinic, HAV, PAD, Nasdaq, Outline of health sciences, Authorization, JAMA, HUMA, Medicine, EAP, FACS, Leadership, Patent, Manuscript, American Medical Association, Injury, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Surgery, Education, Dentistry, Medical device, Pharmaceutical industry, Defense

DURHAM, N.C., June 29, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that an analysis of the potential of the Human Acellular Vessel (HAV) to expand vascular surgical treatment options has been published online in the Journal of the American Medical Association (JAMA) companion journal Surgery.

Key Points: 
  • The JAMA Surgery manuscript , entitled The Human Acellular Vessel (HAV) for Vascular Reconstruction and Bypass, reviews the clinical need for improved options for vascular reconstruction and bypass conduits, and the potential advantages of the HAV over existing approaches.
  • The JAMA Surgery manuscript also highlights clinical data in support of broadly leveraging the HAV in vascular surgical contexts in the future.
  • Further study of the HAV as a long-term conduit for vascular reconstruction and bypass, in many areas where arterial bypass has limited options, is warranted.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.

Retrieved on: 
Monday, June 27, 2022
Patient, Research, Tissue, Vibration, GLOBE, University Hospital Heidelberg, Company, Fast track (FDA), Moyamoya disease, Grade (consulting), German Cancer Aid, Regenerative medicine, University, HAV, Nasdaq, HUMA, Medicine, University of Bonn, Injury, German Cancer Research Center, Johns Hopkins University, Management, Pharmaceutical industry, Defense

DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.

Key Points: 
  • DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Diane Seimetz, Ph.D., to its board of directors.
  • Diane is an innovator and strategist with extensive experience in the biopharmaceutical industry, and we are delighted to welcome her to the Humacyte board, said Kathleen Sebelius, Chair of Humacytes board of directors.
  • Her expertise in guiding companies with innovative products to the market will be invaluable as Humacyte moves toward commercialization of the Human Acellular VesselTM (HAV).
  • Dr. Seimetz brings more than 22 years of international drug development, partnering and managerial experience in the biopharmaceutical industry to the Humacyte board.

Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries

Retrieved on: 
Tuesday, June 21, 2022
FDA, Infection, Amputation, Tissue, Leg, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, National Association Medical Staff Services, Injury, Company, Nursing, HAV, Trauma, AV, United States International Programming to Ukraine and Neighboring Regions, Physician, Fast track (FDA), Vibration, Sale, Nasdaq, HUMA, Food, Medicine, Patient, Moyamoya disease, GLOBE, Risk, Pharmaceutical industry, Defense, Health

Humacyte’s HAVs are engineered replacement vessels designed to be durable, infection-resistant and off-the-shelf to address long-standing limitations in vessel tissue repair and replacement. The first two Ukrainian patients -- one injured by shrapnel and the other by a gunshot wound -- received HAVs earlier this month and are being followed through their recovery. The Ukrainian patient who suffered a severe gunshot wound to the leg had already suffered a failed repair of his artery with a synthetic graft which became infected, and was at risk of limb loss. The HAV implantation restored blood flow to the injured leg.

Key Points: 
  • The implants are part of Humacytes humanitarian relief initiative to provide investigational HAVs to multiple front-line Ukrainian hospitals for the treatment of patients with traumatic injuries.
  • Humacytes HAVs are engineered replacement vessels designed to be durable, infection-resistant and off-the-shelf to address long-standing limitations in vessel tissue repair and replacement.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)

Retrieved on: 
Wednesday, June 8, 2022
HAV, Organ transplantation, Fast track (FDA), Company, Cell, PRA, Food, Annual report, Forward-looking statement, Fresenius Medical Care, Partnership, HUMA, Nasdaq, Sale, FDA, GLOBE, Patient, Injury, Risk, Technology, AV, COVID-19, Antibody, CPRA, SEC, Vibration, Medicine, Tissue, Intention, Terminology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Moyamoya disease, Chronic kidney disease, Pharmaceutical industry, Medical imaging, Defense

DURHAM, N.C., June 08, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today presented data on more than 500 patients-years of exposure demonstrating the investigational Human Acellular Vessel (HAV) does not stimulate an increase in calculated panel reactive antibodies (cPRA) or show evidence of PRA sensitization (de novo cPRA > 20 percent) following HAV implantation. The results are consistent with the absence of HAV rejection in the more than 470 patients implanted with the HAV. The data were presented today at the American Transplant Congress 2022 by Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.

Key Points: 
  • The data were presented today at the American Transplant Congress 2022 by Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte.
  • Prior to tissue and organ transplantation, a routine immunologic measurement of PRA is conducted to estimate the risk of rejection.
  • We now have data on more than 500 patients-years of exposure strongly suggesting that Humacytes HAV does not affect panel reactive antibody levels.
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.

Urban Remedy Recalls Urban Remedy Organic Revitalizing Tea Tonic - Strawberry Hibiscus Rose Due to Possible Hepatitis A Contamination

Retrieved on: 
Saturday, June 4, 2022
HAV, Vaccination, Infection, Headache, Liver disease, Food, Nausea, Fatigue, Abdominal pain, Hepatitis A, Symptoms of COVID-19, LOT, Fever, FDA, Eating, Person, Elektra Records Co. v. Gem Electronic Distributors, Inc., Vomiting, Water, Diarrhea, Drinking, Liver failure, Jaundice, Pharmaceutical industry, Vaccine

RICHMOND, Calif., June 4, 2022 /PRNewswire/ -- Urban Remedy is voluntarily recalling Urban Remedy Organic Revitalizing Tea Tonic Strawberry Hibiscus Rose (LOT 1232 BEST BY 7/17/2022) because it has the potential to be contaminated with Hepatitis A.

Key Points: 
  • RICHMOND, Calif., June 4, 2022 /PRNewswire/ -- Urban Remedy is voluntarily recalling Urban Remedy Organic Revitalizing Tea Tonic Strawberry Hibiscus Rose (LOT 1232 BEST BY 7/17/2022) because it has the potential to be contaminated with Hepatitis A.
  • Urban Remedy contracts Youngstown Grape Distributors Inc. to co-manufacture this product.
  • The product may contain fresh organic strawberries linked to the FDA outbreak investigation of FreshKampo organic strawberries.
  • No illnesses have been reported consuming Urban Remedy product to date.